Related Experiment Video
Updated: Jul 9, 2026

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
Published on: April 21, 2015
TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis
Niklas Finnberg1, Andres J P Klein-Szanto, Wafik S El-Deiry
1Laboratory of Molecular Oncology and Cell Cycle Regulation, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.
Abstract:
Preclinical data support the potential of the death-signaling receptors for TRAIL as targets for cancer therapy. However, it is unclear whether these death-signaling receptors suppress the emergence and growth of malignant tumors in vivo. Herein we show that TNF-related apoptosis-inducing ligand receptor (TRAIL-R), the only proapoptotic death-signaling receptor for TRAIL in the mouse, suppresses inflammation and tumorigenesis. Loss of a single TRAIL-R allele on the lymphoma-prone Emu-myc genetic background significantly reduced median lymphoma-free survival. TRAIL-R-deficient lymphomas developed with equal frequency irrespective of mono- or biallelic loss of TRAIL-R, had increased metastatic potential, and showed apoptotic defects relative to WT littermates. In addition, TRAIL-R-/- mice showed decreased long-term survival following a sublethal dose of ionizing radiation. Histological evaluation of moribund irradiated TRAIL-R-/- animals showed hallmarks of bronchopneumonia as well as tumor formation with increased NF-kappaB p65 expression. TRAIL-R also suppressed diethylnitrosamine-induced (DEN-induced) hepatocarcinogenesis, as an increased number of large tumors with apoptotic defects developed in the livers of DEN-treated TRAIL-R-/- mice. Thus TRAIL-R may function as an inflammation and tumor suppressor in multiple tissues in vivo.
Insights
The TNF-related apoptosis-inducing ligand receptor (TRAIL-R) acts as a crucial tumor suppressor. Loss of TRAIL-R in mice led to increased tumor development, metastasis, and reduced survival, highlighting its role in preventing cancer.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Preclinical studies suggest TRAIL death-signaling receptors are potential cancer therapy targets.
- The in vivo role of these receptors in suppressing tumor emergence and growth remains unclear.
Purpose of the Study:
- To investigate the function of TNF-related apoptosis-inducing ligand receptor (TRAIL-R) as a tumor suppressor in vivo.
- To determine if TRAIL-R deficiency impacts lymphoma development, metastasis, and response to radiation or chemical carcinogens.
Main Methods:
- Utilized Emu-myc mice with TRAIL-R allele loss to study lymphoma development.
- Assessed survival and tumor formation in TRAIL-R knockout mice after sublethal irradiation and diethylnitrosamine (DEN) treatment.
- Histological analysis and NF-kappaB p65 expression were evaluated.
Main Results:
- Loss of TRAIL-R significantly reduced lymphoma-free survival and increased metastatic potential.
- TRAIL-R deficiency led to apoptotic defects in lymphomas and decreased survival after irradiation.
- TRAIL-R knockout mice exhibited increased susceptibility to DEN-induced hepatocarcinogenesis with larger tumors and apoptotic defects.
Conclusions:
- TRAIL-R functions as an in vivo suppressor of inflammation and tumor development.
- TRAIL-R deficiency promotes tumorigenesis and metastasis across multiple tissues.
- TRAIL-R is a critical regulator of apoptosis and immune response in cancer suppression.
Related Concept Videos
Inflammatory Bowel Disease III: Crohn's Disease
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...

